PREDICTION OF PERSONAL HEALTH RISK FACTORS IN METABOLIC SYNDROME

Claus Muss, Selvaraj Y. Subramaniam
International Scientific Society of Applied Preventive Medicine (I-GAP), Private Clinics and I-GAP Research Laboratories, Vienna, Austria

Korespondenční autor: Claus Muss ()

ISSN 1804-7181 (On-line)

Full verze:

Submitted:20. 9. 2010
Accepted: 18. 11. 2010
Published online: 27. 12. 2010

Summary

In European health systems the metabolic syndrome has become of major concern in public health. The same tendency has been observed also in developing countries of South East Asia. The metabolic syndrome is an important health risk factor often related to Diabetes and cardiovascular disease. A successful approach to the prevention of the metabolic syndrome therefore contributes to the stabilization of the present and future health system of the European Union and specific parts of Asia decisively. Practical guidelines for the prevention of diabetes and metabolic syndrome are needed urgently. Laboratory diagnostics provide a practicable tool in the early diagnosis of the metabolic syndrome. In this article new laboratory markers such as Adiponectin, Proinsulin and Asymmetric Dimethylarginine (AD MA) are discussed as markers of metabolic risk.

Keywords: metabolic syndrome; diabetes; Adiponectin, Proinsulin, Asymmetric Dimethylarginine (ADMA)

Literatura

1. Böger RH (2003). The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 59: 824–828.

2. Böger RH, Bode-Böger SM, Szuba A, Tangphao O, Tsao PS, Chan JR, Blaschke TF, Cooke JP (1998). Asymmetric dimethylarginine: A novel risk factor for endothelial dysfunction. Its role in hypercholeste­rolemia. Circulation. 98: 1842–1847.

3. Deveci E, Yesil M, Akinci B, Yesil S, Postaci N, Arikan E, Koseoglu M (2009). Evaluation of insulin resistance in normoglycemic patients with coronary artery disease. Clin Cardiol. 32(1): 32–36.

4. Díez JJ, Iglesias P (2003). The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 148(3): 293–300.

5. Forst T, Pfützner A (2006). Current laboratory parameters in the differential diagnosis of type 2 diabetes mellitus. Proinsulin, adiponectin and others. Dtsch Med Wochenschr. Dec 131 Suppl. 8: S268–S273.

6. Gallagher D (1996). How useful is BMI for comparison of body fatness across age, sex and ethnic groups? American Journal of Epidemiology. (143) 228–239.

7. Garrow JS, Webster J (1985). Quetelet’s index (W/H2) as a measure of fatness. International Journal of Obesity. 9: 147–153.

8. Kennedy A, Martinez K, Chuang C-C, LaPoint K, McIntosh M (2009). Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications. J Nutr. 139(1): 1–4.

9. Kielstein JT, Böger RH, Bode-Böger SM et al. (1999). Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 10: 594–600.

10. Lakka H-M et al. (2002). The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men JAMA. 288: 2709–2716.

11. Lara-Castro C, Fu Y, Chung BH, Garvey WT (2007). Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 18(3): 263– 270.

12. Li H, Lelliott C, Håkansson P, Ploj K, Tuneld A, Verolin-Johansson M, Benthem L, Carlsson B, Storlien L, Michaëlsson E (2008). Intestinal, adipose, and liver inflammation in diet-induced obese mice. Metabolism. 57(12): 1704–1710.

13. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC (2003). Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 24: 1912–1919.

14. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I (2004). Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 24(1): 29–33.

15. Mei Z, Grummer-Strawn LM, Pietrobelli A, Goulding A, Goran MI, Dietz WH (2002). Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents. American Journal of Clinical Nutrition, p. 7597–7985.

16. Miller M (2007). Insulin resistance. Aktuel Ernähr Med. 7(32): 167–174.

17. Nijveldt RJ, Teerlink T, Van der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, van Leeuwen PA (2003). Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr. 22: 23–30.

18. Pfützner A, Pfützner AH, Larbig M, Forst T (2004). Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther. 6(3): 405–412.

19. Pfützner A, Schöndorf T, Seidel D, Winkler K, Matthaei S, Hamann A, Forst T (2006). Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism. 55(1): 20–25.

20. Prentice AM, Jebb SA (2001). Beyond Body Mass Index. Obesity Reviews. 2(3): 141–147.

21. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH (2003). Endothelial dysfunction and raised plasma concentrations of asymmetricdimet­hylarginine in pregnant women who subsequently develop preeclampsia. Lancet. 361: 1511–1517.

22. Stühlinger M, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS (2002). Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. J Am Med Assoc. 287: 1420–1426.

23. Thorens B (2008). Glucose sensing and the pathogenesis of obesity and type 2 diabetes. Int J Obes (Lond). 32 Suppl. 6: S62–S71.

24. Ukkola O, Santaniemi M (2003). Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med. 80(11): 696–702.

25. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992). Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet. 339: 572–575.

26. Vasseur F, Meyre D, Froguel P (2007). Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies. Expert reviews in molecular medicine. 8(27): 1–12.

27. Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich JC, Böger RH (2001). Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet. 358: 2113–2117.

28. 40. EASD-Jahreskongress (2004), European Diabetes-Society, Munich.